Assoc. Prof. Dr. Ningbo Li , Medicinal Chemistry , Shanxi Medical University, China
Dr. Ningbo Li is an accomplished Associate Professor at the School of Basic Medical Sciences, Shanxi Medical University, with a strong academic foundation and a passion for cancer research. With a doctorate in Organic Chemistry from Hunan University, Dr. Li has built a reputable career in green synthesis, targeted nano-drug delivery systems, and near-infrared fluorescent probes molecule for cancer diagnostics and therapy. He has led over 10 national and provincial research projects, published 46 SCI-indexed papers, and holds 5 authorized patents. Dr. Li also contributes to academia through textbooks and serves as a Young Editorial Board Member of Journal of Xiangtan University. His collaborations span leading institutions like Hunan University and Nankai University. With 863 citations and rising influence, Dr. Li is committed to pioneering innovative, low-toxicity cancer therapeutics and translating lab findings into clinical advances.
Professional Profile :
Orcid
Scopus
Summary of Suitability for Award:
Dr. Ningbo Li, Associate Professor at Shanxi Medical University, has demonstrated exceptional research productivity and innovation in the fields of organic chemistry, nanomedicine, and cancer therapeutics. With over 50 SCI-indexed publications, 5 authorized patents, and leadership on more than 10 national and provincial-level research projects, Dr. Li has made significant contributions to targeted cancer treatment and green synthesis of anti-tumor agents. His pioneering work on magnetic nano-drug delivery systems and near-infrared fluorescent probes molecule showcases translational potential for clinical applications in oncology. Furthermore, his involvement in academic book publications, editorial duties, and inter-institutional collaborations reflects both leadership and scholarly impact. With a citation index of 863 and consistent innovation through funded research, Dr. Li exemplifies the qualities of a top-tier researcher. Dr. Ningbo Li is highly suitable for the “Best Researcher Award”, as he meets and exceeds the criteria in terms of research excellence, innovation, scientific impact, and societal relevance. His dedication to advancing cancer research through interdisciplinary chemistry and his strong track record in publications, patents, and funded projects make him a deserving and outstanding candidate for this prestigious recognition
Education:
Dr. Ningbo Li’s academic journey began with a Bachelor’s degree in Chemistry from Shanxi Datong University (2005–2009). He pursued his postgraduate studies at Hunan University, earning a Master’s degree (2009–2012) and subsequently a Ph.D. in Organic Chemistry (2012–2015). His academic training emphasized organometallic chemistry, chiral complex synthesis, and catalysis, laying the groundwork for his future research in drug development and nanomedicine. During his doctoral studies, Dr. Li specialized in chiral Lewis acids, exploring their role in asymmetric synthesis—an area critical to pharmaceutical innovation. His graduate work was pivotal in shaping his later focus on bio-compatible metal complexes and tumor-targeted drug delivery platforms. The integration of organic synthesis with biomedical applications became a hallmark of his educational path, culminating in a multidisciplinary approach that bridges chemistry, nanotechnology, and medical science.
Work Experience:
Dr. Ningbo Li began his academic career as a Lecturer (2015–2018) at the School of Basic Medical Sciences, Shanxi Medical University, where he conducted interdisciplinary research and mentored students. In December 2018, he was promoted to Associate Professor, reflecting his growing contributions to research and teaching. With over a decade in academia, he has supervised numerous graduate projects and continues to develop innovative strategies for targeted cancer therapy using nanomaterials and fluorescent probes. Dr. Li has consistently received competitive research funding from the National Natural Science Foundation of China and the Shanxi Provincial Science Foundations. He also actively contributes to national teaching excellence through authorship in leading organic chemistry textbooks. His dedication to both scientific advancement and student development underscores a career that blends high-impact research with academic leadership in medical and chemical sciences.
Awards:
While specific named awards are not detailed, Dr. Ningbo Li’s academic honors are evident through his prestigious research grants, editorial board appointment, and book contributions. He is the Principal Investigator for multiple national-level research projects, including NSFC Young Scholar Awards, which are highly competitive and indicative of early-career excellence. His appointment as a Young Editorial Board Member of the Journal of Xiangtan University (Natural Science Edition) further reflects his scientific influence and peer recognition. Dr. Li’s patents on chiral zirconium and titanium complexes also highlight his innovative contributions to chemical synthesis. Moreover, his extensive publishing record and the high citation index (863) attest to the impact of his research in organic and medicinal chemistry. Through his involvement in writing authoritative textbooks used in higher education, Dr. Li has contributed significantly to the academic development of students and educators in China.
Research Focus:
Dr. Ningbo Li’s research is centered on the interdisciplinary interface of organic chemistry, nanotechnology, and cancer therapeutics, with a strong emphasis on green and sustainable chemistry. His primary focus lies in the design and synthesis of functionalized magnetic nanocomposites and near-infrared fluorescent probe molecules for the precise diagnosis and targeted treatment of malignant tumors. By engineering magnetic-targeted nano-drug delivery systems, his team aims to achieve site-specific drug accumulation, minimizing systemic toxicity and enhancing therapeutic efficacy. Another key area involves the green synthesis of novel bioactive compounds, particularly chiral organometallic complexes, which exhibit promising anti-tumor properties. His group also explores chiral Lewis acids as catalysts in asymmetric reactions, crucial for the development of structurally complex pharmaceuticals. Dr. Li’s research is highly translational, striving to bridge the gap between bench and bedside by accelerating the clinical application of biocompatible, efficient, and low-toxicity cancer therapeutics rooted in advanced chemical innovation.
Publication Top Notes:
1. g-C₃N₄-Based Heterogeneous Photocatalyzed Synthesis and Evaluation of Antitumor Activities of Fluoroalkylated 4H-Pyrido[1,2-a]pyrimidin-4-ones
2. Magnetic Nanocarriers for pH/GSH/NIR Triple-Responsive Drug Release and Synergistic Therapy in Tumor Cells
3. GSH-Responsive Magnetic Mesoporous Silica Nanoparticles for Efficient Controlled Drug Delivery in Tumor Cells